"This Will Be Worse Than the Great Depression, the Dot-Com Crash, and the 2008 Crisis Combined"

According to Dan Ferris, who has predicted nearly every major market crisis of the last 25 years, a new crisis in the US economy could soon cost you 50% of your portfolio or more if you don't prepare your wealth now. Especially if you're sitting on large gains.

A promising schizophrenia drug showed mixed results. What does that mean for patients?

CARLA K. JOHNSON
October 31, 2024

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

The results underscore the difficulties in treating schizophrenia, a severe mental illness that can cause people to hear voices, feel paranoid and withdraw from others. High dropout rates are typical in schizophrenia drug studies.

Finding a drug that works can be a long ordeal punctuated by crises and hospitalizations. Side effects of existing medications -- weight gain, tremors, restlessness -- cause some people to stop taking medicine and relapse.

There's been great hope among doctors for Cobenfy, which was approved in September, because it acts in the brain differently than other schizophrenia drugs. Instead of blocking dopamine receptors, Cobenfy's main ingredient, xanomeline, works on a different receptor that indirectly blocks dopamine release.

Cobenfy also contains trospium, which blocks some of the side effects. The most common are nausea, vomiting and indigestion. In contrast to the weight gain seen with other schizophrenia drugs, people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb.

Dr. John Krystal of Yale University has led research on other schizophrenia drugs but was not involved in the new studies. He noted that just 10% to 20% of participants in the new studies dropped out because of side effects.

"That is pretty good," he said, noting that fewer or milder side effects could mean people will stay in treatment longer. That could mean fewer problems associated with untreated mental illness: substance use, homelessness and unemployment.

So why did some patients stick with treatment while others dropped out? Krystal said it will be important to understand more about that as doctors start prescribing the drug.

The Food and Drug Administration approved Cobenfy on the strength of two encouraging company-sponsored five-week trials. The latest results announced Thursday at the Psych Congress meeting in Boston come from two longer studies, providing a fuller picture.

In one study, focused on severely ill patients, 78% dropped out, leaving only 35 people for the final analysis. In the other, focused on more stable people, 51% left the study, leaving 283 who took the drug for a year.

"It's not any higher or any lower than what we typically see" in schizophrenia studies, said Dr. Greg Mattingly of Washington University School of Medicine in St. Louis. Mattingly is a consultant for Bristol Myers Squibb and a researcher on one of the studies.

In the more severely ill group, 69% of people had a meaningful improvement in their symptoms at the end of the year. In the other group, 30% saw a meaningful benefit.

Results of interviews with a sample of study participants conducted by an independent research team and shared by Bristol Myers Squibb showed the likelihood of continuing treatment. After six months, 36 said they would continue taking Cobenfy after the trial if given the option; 10 said they would not. Some participants said the drug reduced the voices while others said it didn't work for them.

The estimated yearly cost for Cobenfy is $22,500 compared to $540 for a generic antipsychotic. Krystal and others worry that insurers will require people to try cheaper drugs first before covering Cobenfy.

One cheaper generic called clozapine is widely considered one of the best treatments for schizophrenia, Krystal said. It is underused in the U.S. compared to some other countries because of a cumbersome blood testing program.

The FDA started the blood tests to watch for the risk of severe neutropenia, a rare side effect which can be fatal. But doctors and families have told the FDA that patients have relapsed when their clozapine was withheld or delayed because of the testing requirements.

Sally Littlefield, 29, of Alameda, California, said what works for her is a monthly injection of a long-acting antipsychotic medication. Littlefield, who has schizophrenia and bipolar disorder, wants to learn more about the experiences of people who've taken Cobenfy and not just from players with a financial stake.

Mindy Greiling of Roseville, Minnesota, wants to see data on how Cobenfy compares to clozapine, which works for her 47-year-old son, Jim. Weight gain was a problem for him, but since taking diabetes medication, he's back to his normal weight, Greiling said.

Cobenfy "is getting a lot of ballyhoo, as any new drug does," Greiling said. "It's just a nonstarter for me unless it turns out that it's better than clozapine."

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.

Continue Reading...

Popular

North Korean nationals indicted in scheme using IT workers to funnel money for weapons programs

ST. LOUIS (AP) — Fourteen North Korean nationals have been indicted in a scheme using information technology workers with false identities to contract with U.S. companies — workers who then funneled their wages to for development of ballistic missiles and other weapons, the head of the FBI office in St. Louis said Thursday.

Chanel appoints designer Matthieu Blazy as new artistic director

PARIS (AP) — One of the most prestigious roles in global fashion has just been filled, as appointed Franco-Belgian designer Matthieu Blazy as its new artistic director, the fashion house announced Thursday.

Donald Trump Can't Save You From This Crisis - Ad

A huge economic crisis is about to strike America. 12 months from today, our country could be unrecognizable. That's why I've recorded this video and released it for free. Inside, I lay out exactly what's happening and several critical moves I believe every American should make right now.

Companies tighten security after a health care CEO's killing leads to a surge of threats

“Wanted” posters with the names and faces of health care executives have been popping up on the streets of New York. Hit lists with images of bullets are circulating online with warnings that industry leaders should be afraid.

Crypto Stocks Surge Amid Market Boom - Ad

Crypto stocks are on fire as Bitcoin hits all-time highs. One under-the-radar company is leading the charge, managing $2.1 billion in client assets and seeing record trading volumes. With crypto adoption skyrocketing, this could be a game-changing opportunity.

Costco Q1 Earnings: Can Bullish Momentum Beat The Overbought Blues?

Costco (COST) to report Q1 earnings on Thursday. Stock up 58.01% in past year, 17.32% YTD, but overbought.

Broadcom: Bullish Momentum Builds As Q4 Earnings, Apple Partnership Take Center Stage

Broadcomm (AVGO) to report Q4 earnings on Thursday with expected EPS of $1.38 and revenues of $14.10B. Stock up 70.85% in past year, 22.50% in past 6 months.

Caught On Camera (Shocking New AI Tech) - Ad

AI has already made 500,000 new millionaires over the past two years... The new AI tech you'll see in this video footage will change your life for the better, sooner than you might expect. It will have a bigger impact than the invention of the automobile, personal computer and iPhone, combined...

Suspect in UnitedHealthcare CEO killing charged with murder in New York, court records show

ALTOONA, Pa. (AP) — After on a New York sidewalk, police searched for the masked gunman with dogs, drones and scuba divers. Officers used the city's . Investigators analyzed DNA samples, fingerprints and internet addresses. Police went door-to-door looking for witnesses.

A Southwest jet and a small plane wound up on the same runway after being cleared to land

WASHINGTON (AP) — A Southwest Airlines jet wound up on the same runway with a small private plane that had stopped after an air traffic controller cleared both planes to land on the same California runway in October, according to federal investigators.

This AI Stock Could Lead a $120 Billion Market - Ad

AI stocks are making waves, but the real breakthrough is happening in the $120 billion security robotics market. Autonomous robots are transforming public safety, and one company is ahead of the curve. Timing is everything. Ready to find out more?

Commanders hire Campbell's CEO Mark Clouse as their new team president

WASHINGTON (AP) — The hired Mark Clouse as their new team president Tuesday, putting the longtime food executive in charge of all facets of the organization's business operations when he starts in late January.

French Government Collapses After Vote Of No Confidence

The French government collapsed on Wednesday following a successful no-confidence vote, throwing France, the eurozone's second-largest economy, into political turmoil.

Is a Starlink IPO Coming in 2024? - Ad

Could there be signs that a Starlink IPO is set for the second half of 2024? According to one top venture capitalist, the answer is YES! And for the first time ever, you have the rare chance to profit pre-IPO... BEFORE Starlink goes public.

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some and future products.

Gates-Backed Company Holds the Future of AI - Ad

Bill Gates is making his next big bet. And this time, it's with artificial intelligence. Over the last several years, Gates has quietly invested more than $750 million into this technology. And he's not the only one. Warren Buffett, Peter Thiel, Jeff Bezos, and others are in on it too. In this new exposé, Porter Stansberry shares all the details.

China bans exports to US of gallium, germanium, antimony in response to chip sanctions

BANGKOK (AP) — China announced Tuesday it is banning exports to the United States of gallium, germanium, antimony and other key high-tech materials with potential military applications.

Is NVDA a Sell? Buy This Stock Instead Before Dec. 31 - Ad

After soaring over 150% in 2024 alone... is it actually time to buy Nvidia? A 50-year Wall Street veteran gives his answer to Nvidia, right here... Including the name and ticker of one under-the-radar AI stock to buy instead of Nvidia... before Tuesday, December 31st.

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

44 years after New York couple vanished, car matching description of theirs is found in Georgia

BRUNSWICK, Georgia (AP) — A car similar to one driven by a wealthy New York couple missing for more than four decades has been found in a south Georgia pond near the hotel where they were last seen, police in Georgia said.

Crypto Stocks Surge Amid Market Boom - Ad

Crypto stocks are on fire as Bitcoin hits all-time highs. One under-the-radar company is leading the charge, managing $2.1 billion in client assets and seeing record trading volumes. With crypto adoption skyrocketing, this could be a game-changing opportunity.

[VIDEO] Watch Cannabis Farm Rattled By California's 7.0 Earthquake

Watch Humboldt Flower Company earthquake footage as a magnitude 7 quake shakes cannabis grow room, triggering a tsunami warning in California.

A $50 Backdoor Play On Elon's Next "Super-IPO"? - Ad

Elon Musk has become Trump's most trusted advisors. According to one legendary investor... We are leading up to the world's first "Super-IPO" -- a company creating over $100 billion on the first day it goes public! Knowing about this "backdoor" play could be the best way to profit before the IPO...Starting with as little as $50.

Top 3 Energy Stocks That Could Blast Off In December

When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term.

French government faces no-confidence vote over Barnier's austerity budget

PARIS (AP) — is bracing for a no-confidence vote this week, a political reckoning almost certain to topple his fragile government and send shockwaves across the eurozone.

Crypto Stocks Are Heating Up - Ad

At the center of this transformation is a game-changing platform that's experiencing explosive growth with $41 million in revenue in just nine months. The stock has doubled in the last 45 days, but this is only the beginning.

Oil delivery to the Czech Republic from Russia through the Druhzba pipeline is interrupted

PRAGUE (AP) — Oil delivery to the Czech Republic from Russia through the Druhzba pipeline has been interrupted, Czech officials said Wednesday.

Nvidia, AMD, C3 ai, Oracle, Tesla: Why These 5 Stocks Are On Investors' Radars Today?

On Monday, major U.S. indices closed in the red, with the Dow Jones Industrial Average falling 0.5% to 44,401.93.

December 16th - The Biggest Crypto Event in History - Ad

According to the man who called every major market top and bottom for the last 29 years... A single event triggering on November 18th will send the crypto market soaring. But what's more exciting... is that this event could send a small sector of the crypto market soaring 5X, 25X, and even 100X higher in just days.

Stocks to Buy (and Sell) Before Inauguration Day

Experts predict Trump's policies will positively affect energy, finance, defense sectors; stocks to buy include EPD, JPM, LMT, while others may decline.

Is This Defi Coin Your Next "10-Bagger" Investment? - Ad

Our #1 pick in decentralized finance is largely overlooked by mainstream investors (for now). This governance token could skyrocket as DeFi adoption surges with the smart money and institutions.

Top 3 Consumer Stocks That May Keep You Up At Night This Quarter

Three stocks in the consumer discretionary sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Google's Willow Quantum Computing Chip Sparks Stellar Conversation Between Elon Musk And Sundar Pichai: 'Most Obvious Path Is Staring At Our Eyes'

Google CEO Sundar Pichai and Elon Musk discussed ambitious technological possibilities, from leveraging quantum computing advancements like Google's Willow chip to envisioning solar-powered quantum clusters in space, highlighting their shared focus on transformative innovation.

10 Billion Humanoid Robots on Planet Earth? - Ad

Maybe growing up, you imagined we'd all have our own personal "robot butler" roving around our home doing what we command. Believe it or not, but that's EXACTLY what will soon happen with this new "Bot Com Revolution." Elon Musk is predicting 10 billion humanoid robots by 2040. Even more amazing, Musk predicts these robots could cost only $20,000 each -- about the cost of a good used car!

Larger Fonts, Bigger Impact: iQIYI Makes Entertainment More Accessible

iQIYI introduces 'Extra Large Font' feature to enhance accessibility for senior and visually impaired users.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright finstrategist.com
Privacy Policy | Terms of Service